Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab and Trastuzumab in HER2-Positive Metastatic Breast Cancer
NCT01674062Phase 2Completed
- Sponsor
- Roche
- Start
- May 2006
- Primary completion
- Feb 2008
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of pertuzumab in HER2-positive breast cancer, sponsored by Roche. Started May 2006; status: completed.
02
Drugs
pertuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01674062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01674062.